文献速递甲状腺疾病

家族性腺瘤性息肉病患者所患甲状腺癌反复携带APC、BRAF和KMT2D体细胞变异

Thyroid Carcinomas That Occur in Familial Adenomatous Polyposis Patients Recurrently Harbor Somatic Variants in APC, BRAF, and KTM2D.
PubMed 文献 · Thyroid · 2020-01-01

对12例家族性腺瘤性息肉病(FAP)合并甲状腺乳头状癌(PTC)患者的配对肿瘤与正常DNA行全基因组测序,7例有APC体细胞突变、7例有KMT2D体细胞突变,仅2例有BRAF p.V600E突变;6例筛状-桑葚样变异型(PTC-CMV)全部有APC体细胞突变,提示FAP相关PTC突变谱与散发性PTC不同。

要点

  • 12例FAP相关PTC中7例存在APC体细胞突变,7例存在KMT2D体细胞突变。
  • 仅2例肿瘤携带BRAF p.V600E体细胞突变,该突变在散发性PTC中最常见。
  • 6例PTC-CMV组织学肿瘤全部有APC体细胞突变,APC第二打击与PTC-CMV相关。

核心结论

  • FAP相关PTC通常具有与散发性PTC不同的突变谱,约半数FAP患者甲状腺癌存在APC体细胞第二打击且与PTC-CMV组织学相关,部分FAP患者出现BRAF p.V600E体细胞变异属新发现。

研究设计与样本

  • 对12例发生PTC的FAP患者的配对甲状腺肿瘤与正常DNA行全基因组测序,并将体细胞突变谱与临床特征及既往测序的散发性PTC病例比较,同时行胚系变异谱分析。

主要发现

  • 全部12例患者均携带APC胚系突变,符合FAP。
  • 7例患者有APC体细胞突变,7例患者有KMT2D体细胞突变,这些基因突变在散发性PTC中极罕见。
  • 仅2例肿瘤携带BRAF p.V600E体细胞突变。
  • 6例肿瘤为PTC-CMV组织学,且全部6例均有APC体细胞突变。
  • 9例FAP-PTC患者携带既往与甲状腺癌相关的基因的罕见胚系变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出除APC外其他基因的胚系变异(本系列12例中9例)的作用需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Familial adenomatous polyposis (FAP) is a condition typically caused by pathogenic germline mutations in the APC gene. In addition to colon polyps, individuals with FAP have a substantially increased risk of developing papillary thyroid cancer (PTC). Little is known about the events underlying this association, and the prevalence of somatic "second-hit" mutations in APC is controversial. Methods: Whole-genome sequencing was performed on paired thyroid tumor and normal DNA from 12 FAP patients who developed PTC. Somatic mutation profiles were compared with clinical characteristics and previously sequenced sporadic PTC cases. Germline variant profiling was performed to assess the prevalence of variants in genes previously shown to have a role in PTC predisposition. Results: All 12 patients harbored germline mutations in APC, consistent with FAP. Seven patients also had somatic mutations in APC, and seven patients harbored somatic mutations in KMT2D, which encodes a lysine methyl transferase. Mutation of these genes is extremely rare in sporadic PTCs. Notably, only two of the tumors harbored the somatic BRAF p.V600E mutation, which is the most common driver mutation found in sporadic PTCs. Six tumors displayed a cribriform-morular variant of PTC (PTC-CMV) histology, and all six had somatic mutations in APC. Additionally, nine FAP-PTC patients had rare germline variants in genes that were previously associated with thyroid carcinoma. Conclusions: Our data indicate that FAP-associated PTCs typically have distinct mutations compared with sporadic PTCs. Roughly half of the thyroid cancers that arise in FAP patients have somatic "second-hits" in APC, which is associated with PTC-CMV histology. Somatic BRAF p.V600E variants also occur in some FAP patients, a novel finding. We speculate that in carriers of heterozygous pathogenic mutations of tumor suppressor genes such as APC, a cooperating second-hit somatic variant may occur in a different gene such as KTM2D or BRAF, leading to differences in phenotypes. The role of germline variance in genes other than APC (9 of the 12 patients in this series) needs further research.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nieminen TT, Walker CJ, Olkinuora A, et al. Thyroid Carcinomas That Occur in Familial Adenomatous Polyposis Patients Recurrently Harbor Somatic Variants in APC, BRAF, and KTM2D. Thyroid. 2020. PMID: 32024448. doi:10.1089/thy.2019.0561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。